Goldman Sachs
NAMS icon

Goldman Sachs’s NewAmsterdam Pharma NAMS Stock Holding History

Goldman Sachs’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.4M Sell
1,544,911
-401,463
-21% -$13.2M ﹤0.01% 1762
2026
Q1 		$62.3M Buy
1,946,374
+220,712
+13% +$7.19M 0.01% 1400
2025
Q4 		$60.5M Buy
1,725,662
+845,110
+96% +$30.8M 0.01% 1349
2025
Q3 		$25M Sell
880,552
-69,428
-7% -$1.66M ﹤0.01% 2041
2025
Q2 		$17.2M Buy
949,980
+330,417
+53% +$6.03M ﹤0.01% 2263
2025
Q1 		$12.7M Sell
619,563
-35,147
-5% -$781K ﹤0.01% 2467
2024
Q4 		$16.8M Buy
654,710
+620,637
+1,821% +$13.2M ﹤0.01% 2304
2024
Q3 		$566K Buy
34,073
+8,686
+34% +$150K ﹤0.01% 4980
2024
Q2 		$488K Sell
25,387
-1,258,068
-98% -$25.2M ﹤0.01% 4844
2024
Q1 		$30.4M Sell
1,283,455
-100,866
-7% -$2.05M 0.01% 1515
2023
Q4 		$15.5M Buy
+1,384,321
New +$12.7M ﹤0.01% 2149

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Goldman Sachs's NAMS Position: Q2 2026 in Review

Goldman Sachs reduced its NewAmsterdam Pharma (NAMS) stake by 21% in Q2 2026, selling an estimated $13.2M and leaving 1,544,911 shares worth $52.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1762.

Goldman Sachs first reported a position in NAMS in Q4 2023 and has held it in 11 quarters since. The position peaked at $62.3M in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Goldman Sachs held 1,544,911 shares of NewAmsterdam Pharma worth $52.4M as of Q2 2026.
  • Goldman Sachs sold 401,463 NewAmsterdam Pharma shares in Q2 2026, an estimated $13.2M.
  • NewAmsterdam Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1762 holding.
  • Goldman Sachs first reported a position in NewAmsterdam Pharma in Q4 2023 and has held it in 11 quarters since.
  • Goldman Sachs's NewAmsterdam Pharma position peaked at $62.3M in Q1 2026.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.